Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: CALGB-50402
NCT Study ID (ClinicalTrials.gov): NCT00117975
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Myron S. Czuczman, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving more than one monoclonal antibody may be a better way to block cancer growth.
PURPOSE: This phase II trial is studying how well giving rituximab together with galiximab works in treating patients with stage II, stage III, or stage IV non-Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information